




[Fig. 1]




[Fig. 2]




[Fig. 3]



[Fig. 4]



[Fig. 5]




Lanes 1-7: Strains prepared in Example 1


Lane 8: NIHONBARE (Non-Transformant)

Lane 9 A strain prepared in Example 1


[Fig. 6]




[Fig. 7]




[Fig. 8]




[Fig. 9]



[Fig. 10]




[Fig. 11]







[Fig. 12]




[Fig. 13]



[Fig. 14]



[Fig. 15]



native : GLP-1(7-36amide)

34N : [Ser8,Gln26,Asn34]-GLP-1(7-36)

34D : [Ser8,Gln26,Asp34]-GLP-1(7-36)

5 : 5  $\mu$ g/kg Subcutaneous administration

20 : 20  $\mu$ g/kg Subcutaneous administration